Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculation
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of infectious diseases
3.2.1.2 Advancements in RNA delivery technologies
3.2.1.3 Increasing partnerships and collaborations among market players
3.2.2 Industry pitfalls & challenges
3.2.2.1 Recall of RNA therapeutic products
3.2.2.2 High cost of development and manufacturing
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Vaccines
5.3 Drugs
Chapter 6 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 mRNA therapeutics
6.3 Antisense oligonucleotide (ASO) therapeutics
6.4 siRNA (small interfering RNA) therapeutics
6.5 RNA interference (RNAi) therapeutics
6.6 Other types
Chapter 7 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Infectious diseases
7.3 Hereditary/genetic diseases
7.4 Autoimmune disorders
7.5 Other indications
Chapter 8 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
8.1 Hospitals
8.1.1 Private
8.1.2 Public
8.2 Academic & research institutes
8.3 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Alnylam Pharmaceuticals, Inc.
10.2 Arrowhead Pharmaceuticals, Inc.
10.3 BioNTech SE
10.4 Ionis Pharmaceuticals
10.5 Moderna Inc.
10.6 Novartis AG
10.7 Orna Therapeutics, Inc.
10.8 Pfizer Inc.
10.9 Sanofi
10.10 Sarepta Therapeutics, Inc.
